A Phase I/II Open-label Study of MCS110 in Patients With Prostate Cancer and Bone Metastases

• Status: Terminated
• Trial end date: 2009-08-01
• Target enrollment: 0
• Participant gender: Male

Summary

This study will evaluate the safety and efficacy of MCS110 in patients with prostate cancer and bone metastases

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals

Criteria

Inclusion Criteria:

• Patients with asymptomatic castrate-resistant prostate cancer with bone metastases who have not received any bisphosphonates in the 12 months prior to enrollment

• 18 years old and over

Exclusion Criteria:

• Plan to be on cytotoxic or biologic therapy during study

• Active dental problems

• Active heart complications

• Active infection

• Patients with moderate to severe swelling due to fluid

Other protocol-defined inclusion/exclusion criteria may apply